SCHEMBL14730786

SCHEMBL14730786

COC(=O)c1ccc2[nH]c3c(c2c1)C1(CCC1)CC(C)(C)C3=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
MDH2 P40926 1/20 0.47
GSK3B P49841 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
MAPKAPK2 P49137 3/20 0.45
KIF11 P52732 2/20 0.43
ALOX15 P16050 2/20 0.42
CASP1 P29466 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14730707 0.88 MAPKAPK2 (0.42) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL14730846 0.88 KDM4E (0.51) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL13248585 0.81 MAPKAPK2 (0.69) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL14730718 0.80 HSD17B10 (0.51) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL14730704 0.80 KDR (0.43) MAPKAPK2NPC1RAB9AFLT3MAPK1
SCHEMBL14730809 0.79 ALK (0.44) ALDH1A1ALOX15NPC1RAB9AKMT2A
SCHEMBL14730692 0.77 KDM4E (0.50) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL14730760 0.77 KDM4E (0.50) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL3002604 0.75 MAPKAPK2 (0.67) CCNB2CDK1CCNB1MDH2GSK3B
SCHEMBL14731467 0.75 CCNB2 (0.42) CCNB2CDK1CCNB1MDH2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
WO-2013026163-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS HCCS, C1R, HAVCR2 CCNB2 325/4885CDK1 223/4885CCNB1 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.